DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,232,265 B2 Rogers Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,232,265 B2 Rogers Et Al US008232265B2 (12) United States Patent (10) Patent No.: US 8,232,265 B2 Rogers et al. (45) Date of Patent: Jul. 31, 2012 (54) MULTI-FUNCTIONAL IONIC LIQUID 25. A 8. 3. MadeuZZi et al. ..... : COMPOSITIONS FOR OVERCOMING 4,491,574 A 1/1985 Seifter et al. .................... 424/10 POLYMORPHISMAND IMPARTING 4,761,164 A 8, 1988 Pez et al. .......................... 55/16 IMPROVED PROPERTIES FORACTIVE 4,973,456 A 1 1/1990 Quinn et al. 423,210.5 PHARMACEUTICAL, BIOLOGICAL, 539W - I A s 3: E.OCSC heralCal. ............. $2. NUTRITIONAL AND ENERGETIC 5,679,146 A 10/1997 Kalt et al. .......... ... 106,166.01 INGREDIENTS 5,683,832 A 1 1/1997 Bonhote et al. ............... 429,111 5,731, 101 A 3, 1998 Sherifet al. ....... ... 429,102 (75) Inventors: Robin D. Rogers, Tuscaloosa, AL (US); 5,792,399 A 8, 1998 Meister et al. ... 264/101 Daniel T. Daly, Tuscaloosa, AL (US); 5,827,602 A 10, 1998 Koch et al. ..... ... 429,194 Richard P. Swatloski, Tuscaloosa, AL 993,--- f $3. E.urgard et al......................... .. 428/402.2 556,119 (US); Whitney L. Hough, Albertville, 6,774,240 B2 8/2004 Seddon et al. ..... ... 548/347.1 AL (US); James Hilliard Davis, Jr., 6,808,557 B2 10/2004 Holbrey et al. .......... 106,163.01 Mobile, AL (US); Marcin Smiglak, 6,824,599 B2 11/2004 Swatloski et al. ....... 106,163.01 6,846,926 B1 1/2005 Koppes et al. ................ 544,198 oznanCNE (PL); Scottork K. Spear,St. EasSLOn, 6,924.3416,906,004 B2 * 8/20056/2005 MaysParrish et et al. al. ....................... 504,127526,89 AL (US) 6,939,882 B1 9/2005 Cooke et al. ... ... 514,336 6,939,974 B2 9/2005 Earle et al. .. 548/347.1 (73) Assignee: Board of Trustees of the University of 7,166,641 B2 * 1/2007 Lee et al. ... ... 514,561 Alabama, Tuscaloosa, AL (US) 2002/0010291 A1 1/2002 Murphy ............. 526,133 s s 2002/0161261 A1 10, 2002 Bahrmann et all 564,281 - 2003, OO73604 A1 4, 2003 McGolfetal. 510,441 (*) Notice: Subject to any disclaimer, the term of this 2004.0007693 A1 1/2004 Moulton ........ ... 252/.364 patent is extended or adjusted under 35 2004/0026.666 A1 2/2004 Chauvin et al. ............... 252/364 U.S.C. 154(b) by 1208 days. 2004/0146549 A1 7/2004 Ben-Sasson et al. ......... 424/449 2004/0234966 Al 11/2004 Bryning et al. ................... 435/6 (21) Appl No.: 11A545,938 2005/OO587O2 A1 3/2005 Ben-Sasson et al. ......... 424/452 y x- - - 9 2005/0136103 A1 6/2005 Ben-Sasson et al. ......... 424/449 (22) Filed: Oct. 10, 2006 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2007/0093462 A1 Apr. 26, 2007 CA 2619367 A1 T 2009 (Continued) Related U.S. Application Data (60) Provisional application No. 60/764,850, filed on Feb. OTHER PUBLICATIONS 2, 2006, provisional application No. 60/724,604, filed Avent et al., “Evidence for hydrogen bonding in solutions of 1-Ethyl on Oct. 7, 2005, provisional application No. 3-imidazolium Halides, and its implications for ambient temperature 60/724,605, filed on Oct. 7, 2005. Halogenoaluminate(III) ionic liquids.” J. Chem. Soc., Dalton Trans., 3405 (1994). (51) Int. Cl. Bates et al., "CO2 capture by a task-specific ionic liquid.” J. Am. A6 IK3I/33 (2006.01) Chem. Soc. 124(6): 926-927 (2002). A6 IK3I/445 (2006.01) Bernstein, “Polymorphism of high energy materials.” Polymorphism A6 IK3I/21 (2006.01) in Molecular Crystals, 275-296 (2002). A6 IK3I/24 (2006.01) Bernstein, “Introduction and historical background.” Polymorphism A6 IK3I/6 (2006.01) in Molecular Crystals, 1-28 (2002). AOIN 43/90 (2006.01) Bernstein, “Crystal structure prediction and polymorphism.” ACA AOIN 37/30 (2006.01) Transactions, 39:14-23 (2004). AOIN37/18 (2006.01) (52) U.S. Cl. ........ 514/183; 514/306; 514/330; 514/513; (Continued) 514/535; 514/555 Primary Examiner — Alton Pryor (58) Fieldee application t state file for completeSeash - -search - - - - - - - -hhi history. - - - - - - - - None &(74) Curfman, Attorney, LLC Agent, or Firm — McKeon, Meunier, Carlin (56) References Cited (57) ABSTRACT U.S. PATENT DOCUMENTS Disclosed are ionic liquids and methods of preparing ionic 1943,176 A 1/1934 Graenacher ................... 260/100 liquid compositions of active pharmaceutical, biological, 2,004,891 A * 6/1935 Goldberg ...................... 514,533 nutritional, and energetic ingredients. Also disclosed are 3,223,704 A 12, 1965 Shibe ... ... 260,247.1 methods of using the compositions described herein to over 3. As A 3. E. St. .364;2. come polymorphism, overcome solubility and delivery prob 3.47 1423 A 10, 1969 Elmer ....... ... 260/22 lems, to control release rates, add functionality, enhance effi 4,104,368 A 8, 1978 Lala et al. 424,60 cacy (synergy), and improve ease of use and manufacture. 4,171,352 A * 10/1979 Wolgemuth et al. ... 436/86 4,188,263. A 2, 1980 Hulsmann et al. ............ 439/179 9 Claims, 6 Drawing Sheets US 8,232,265 B2 Page 2 U.S. PATENT DOCUMENTS Cuppen et al., “Crystal structure and growth behavior of aspartame 2005, 0194561 A1 9/2005 Davis .............................. 252/67 form I-A.” Crystal Growth & Design, 5(3) 917-923 (2005). 2005/0232981 A1 10, 2005 Ben-Sasson .................. 424/448 Davis et al., “Thiazolium-ion based organic ionic liquids (OILS). 2006, O159632 A1 7/2006 Ishibashi et al. Novel OILs which promote the benzoin condensation.” Tetrahedron 2007/0053939 A1 3/2007 Yokoyama et al. Lett. 40: 1621-1622 (1999). 2007/0054952 A1 3/2007 Hamamoto et al. Davis et al., From curiosities to commodities: Ionic liquids begin the 2009,0264664 A1 10, 2009 Endo et al. 2010, 0004608 A1 1/2010 Hamamoto et al. transformation, Chem. Comm. 1209-1211 (2003). 2010.00297.04 A1 2/2010 Hanma et al. Domagk, "A new class of disinfectants.” Deut. Med. Wochenschr. 61:829 (1935). FOREIGN PATENT DOCUMENTS Dupont et al., “Room temperature molten salts: Neuteric "Green” DE 93-43O8410 3, 1993 Solvents for chemical reactions and processes.” Braz. Chem. Soc. EP 1405646 * 4, 2004 11(4):337-344 (2000). ES 8406412 4f1983 Elaiwi et al., “Hydrogen bonding in Imidazolium salts and its impli FR 1404697 5, 1965 cations for ambient-termperature Halogenoaluminate (III) ionic liq GB 869149 5, 1961 GB 1067094 5, 1964 uids.” Chem. Soc., Dalton Trans., 3467 (1995). GB 1473.603 5, 1971 Fanninet al., “Properties of 1,3-Dialkylimidazolium chloride-alumi JP 61-236818 10, 1986 num chloride ionic liquids. 2. Phase transitions, densities, electrical JP 62-198609 9, 1987 conductivities, and viscosities,” J. Phys. Chem... 88:2614-2621 JP 63-0565O1 3, 1988 (1984). JP 2005-82512 3, 2005 Fraga-Dubreuil et al., “Grafted ionic liquid-phase-supported synthe JP 2005 082512 3, 2005 sis of Small organic molecules.” Tetrahedron Lett. 42:6097-6100 JP 2005082512. A 3, 2005 NL 3O2478 10, 1965 (2001). WO WO95/21806 8, 1995 Freemantle, "Ionic liquids show promise for clean separation tech WO WO95/21871 8, 1995 nology.” Chem. Eng. News, 76(34):34 (1998). WO WO95/21872 8, 1995 Freemantle, “Eyes on ionic liquids.” Chem. Eng. News, 78(2):37-50 WO WO 97/43012 11, 1997 (2000). WO WO 98.51283 11, 1998 Fukumoto et al., “Room temperature ionic liquids from 20 natural WO WO98.51283 A1 11, 1998 amino acids.” J. Am. Chem. Soc. 2398-2399 (2005). WO WOO3,O29329 4/2003 WO WO 2004/O75877 9, 2004 Geppi et al., “Molecular properties of ibuprofen and its solid disper WO WO 96.06593 3, 2006 sions with eudragit RL100 studied by Solid-state nuclear magnetic WO WO 2009/060629 A1 5, 2009 resonance.” Pharm. Res., 22(9) 1544-1555 (2005). WO WO 2009,066457 A1 5/2009 Gordon et al., "Fused organic salts. 8. Properties of molten straight WO WO 2009,075094 A1 6, 2009 chain isomers of tetra-N-pentylammonium salts.” J. Amer: Chem. WO WO 2009,119836 A1 10/2009 Soc. 100(24):7445-7454 (1978). Hamaguchi et al., “Structure of ionic liquids and ionic compounds: OTHER PUBLICATIONS Are ionic liquids genuine liquids in the conventional sense.” Bhatt et al., “Saccharin as a salt former. Enhanced solubilities of Advances in Chem. Physics, 131:85-104 (2005). Saccharinates of active pharmaceutical ingredients.” Chem. Comm., Hartman et al., "Acid soaps,” J. Applied Chem., 41: 127 (1928). 1073-1075 (2005). Haynes et al., “Occurrence of pharmaceutically acceptable anions Black et al., “Increased chemical purity using a hydrate.” Crystal and cations in the Cambridge structural database.” J. Pharm. Sci., Growth & Design, 4(3) 539-544 (2004). 94(10) 2111-2120 (2005). Bonhote et al., “Hydrophobic, highly conductive ambient Holbrey et al., “Ionic liquids.” Clean Products and Processes 1:223 termperature molten salts.” Inorg. Chem. 35:1168-1178 (1996). 236 (1999). Bowlas et al., “Liquid crystalline ionic liquids.” Chem. Comm. 1625 Holbrey et al., “The phase behaviour of 1-alkyl-3-methlimidazolium (1996). tetrafluoroborates; Ionic liquids and ionic liquid crystals. J. Chem. Browning et al., “Relationships between antiseptic action and chemi Soc. Dalton Trans., 2133-2139 (1999). cal constitution with special reference to compounds of the pyridine, Huddleston et al., “Characterization and comparison of hydrophilic quinoline, acridine and phenazine seriers.” Proc. Royal Soc. London, and hydrophobic room temperature ionic liquids incorporating the 93(653):329-366 (1922). imidazolium cation.” Green Chem., 3:156-164 (2001). Browning et al., “The antiseptic properties of the amino derivatives of International Search Report and Written Opinion of the International styryl and anil quinoline.” Proc. Royal Soc. London, 100(703):293 Searching Authority for PCT/US06/39454. 325 (1926). Jacobs et al., “On a new group of bactericidal Substances obtained Butcher et al., “Initial screening trials of some quaternary ammonium from hexamethylenetetramine.” Proc.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Lifestyle Drugs” for Men and Women
    Development of “Lifestyle Drugs” for Men and Women Armin Schultz CRS - Clinical Research Services Mannheim GmbH AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Smart drugs, Quality-of-life drugs, Vanity drugs etc. Lifestyle? Lifestyle-Drugs? Active development? Discovery by chance? AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle A lifestyle is a characteristic bundle of behaviors that makes sense to both others and oneself in a given time and place, including social relations, consumption, entertainment, and dress. The behaviors and practices within lifestyles are a mixture of habits, conventional ways of doing things, and reasoned actions „Ein Lebensstil ist [...] der regelmäßig wiederkehrende Gesamtzusammenhang der Verhaltensweisen, Interaktionen, Meinungen, Wissensbestände und bewertenden Einstellungen eines Menschen“ (Hradil 2005: 46) Different definitions in social sciences, philosophy, psychology or medicine AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle Many “subdivisions” LOHAS: “Lifestyles of Health and Sustainability“ LOVOS: “Lifestyles of Voluntary Simplicity“ SLOHAS: “Slow Lifestyles of Happiness and Sustainability” PARKOS: “Partizipative Konsumenten“ ……. ……. ……. AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Lifestyle drug is an imprecise term commonly applied to medications which treat non-life threatening and non-painful conditions such as baldness, impotence, wrinkles, or acne, without any medical relevance at all or only minor medical relevance relative to others. Desire for increase of personal well-being and quality of life It is sometimes intended as a pejorative, bearing the implication that the scarce medical research resources allocated to develop such drugs were spent frivolously when they could have been better spent researching cures for more serious medical conditions.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Modafinil and Modafinil Analogues: Free Radical Mechanism of the Eugeroic and Cognitive Enhancment Effect Clifford Fong
    Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect Clifford Fong To cite this version: Clifford Fong. Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect. [Research Report] Eigenenergy. 2018. hal-01933737 HAL Id: hal-01933737 https://hal.archives-ouvertes.fr/hal-01933737 Submitted on 24 Nov 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect Clifford W. Fong Eigenenergy, Adelaide, South Australia. Keywords: Modafinil, modafinil-like analogues, eugeroic effect, cognitive enhancement, free radicals, quantum mechanics Abbreviations Dopamine DA, dopamine transporter DAT, Dissociative electron transfer or attachment DET, Linear free energy relationship LFER, free energy of water desolvation ΔG desolv,CDS , lipophilicity free energy ΔG lipo,CDS, cavity dispersion solvent structure of the first solvation shell CDS, highest occupied molecular orbital HOMO, lowest unoccupied molecular orbital LUMO, multiple correlation coefficient R 2, the F test of significance, standards errors for the estimate (SEE) and standard errors of the variables SE(ΔG desolCDS ), SE(ΔG lipoCDS ), SE(Dipole Moment), SE (Molecular Volume), transition state TS, reactive oxygen species ROS.
    [Show full text]
  • <I>Iguana Iguana</I>
    Journal of the American Association for Laboratory Animal Science Vol 58, No 6 Copyright 2019 November 2019 by the American Association for Laboratory Animal Science Pages 810–816 Use of Rodent Sedation Tests to Evaluate Midazolam and Flumazenil in Green Iguanas (Iguana iguana) Thais F Bressan, Thayanee Sobreira, and Adriano B Carregaro* This study aimed to evaluate the applicability of rodent behavioral tests to assess the effects of midazolam and flumazenil in green iguanas. Four tests commonly used to assess sedation in rodents—the open field test, forced swim test, behavioral scale, and traction test—were conducted in 10 juveniles iguanas. The animals received midazolam (2 mg/kg IM) or 0.9% NaCl (0.4 mL/kg IM), and the tests were conducted between 0 and 300 min thereafter. To verify the effects of midazolam and flumazenil, the most informative tests from the evaluation stage and the limb withdrawal latency time (LWLT) were used. All 10 iguanas were tested under 4 conditions, as follows: MS, midazolam (2 mg/kg IM), followed 30 min later by 0.9% NaCl (0.4 mL/kg IM); FS, flumazenil (0.05 mg/kg IM), followed by 0.9% NaCl (0.4 mL/kg IM) 30 min later; MF, midazolam (2 mg/ kg IM), followed by flumazenil (0.05 mg/kg IM) 30 min later; and CON, 0.9% NaCl (0.4 mL/kg IM). The behavioral scale and the forced swim test showed the best detection of the onset, peak effect, and the differences between the sedated and con- trol iguanas, with testing done between 15 and 240 min after drug administration.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • Redalyc.Tissue Depletion of Azaperone and Its Metabolite
    Revista de Toxicología ISSN: 0212-7113 [email protected] Asociación Española de Toxicología España Mestorino, N.; Marchetti, M. L.; Daniele, M.; Martínez, M. A.; Martínez-Larrañaga, M. R.; Anadón, A. Tissue depletion of azaperone and its metabolite azaperol after oral administration of azaperone in food-producing pigs Revista de Toxicología, vol. 30, núm. 2, julio-diciembre, 2013, pp. 209-214 Asociación Española de Toxicología Pamplona, España Available in: http://www.redalyc.org/articulo.oa?id=91931189013 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Rev. Toxicol. (2013) 30: 209-214 Tissue depletion of azaperone and its metabolite azaperol after oral administration of azaperone in food-producing pigs Mestorino N1* , Marchetti M L1 , Daniele M1 , Martínez M A2 , Martínez-Larrañaga M R2 , Anadón A2 . 1Laboratorio de Estudios Farmacológicos y Toxicológicos (LEFyT), Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, 1900- La Plata, Buenos Aires, Argentina. 2Departamento de Toxicología y Farmacología, Facultad de Veterinaria, Universidad Complutense de Madrid, 28040-Madrid, España. Recibido 5 de noviembre de 2013 / Aceptado 20 de diciembre de 2013 Abstract: Azaperone is a butyrophenone tranquilizer for swine. establecidos por la Unión Europea (100 mg / kg en el músculo, el Food producing pigs are particularly sensitive to stress during hígado, los riñones y la piel + grasa) en ningún momento del handling and transport to the abattoir. In vivo, azaperone is partially muestreo. Como consecuencia, según los resultados obtenidos en el metabolised to azaperol, a metabolite with pharmacological activity.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]